top of page
spyglass_logo_side.jpg

COMMITMENT TO INNOVATION

SpyGlass Pharma™ brings together our industry's brightest engineers, scientists and clinicians to develop life-changing treatment options for patients suffering from ophthalmic diseases. Together we work toward our singular focus: Long-term drug delivery—that lasts.

FOUNDING SPYGLASS PHARMA™

An Unmet Need and a Partnership in Ophthalmic Innovation Reveals New Opportunities

Malik Kahook, MD and Glenn Sussman have been working together on ophthalmic innovations for over 15 years, leveraging their respective skills as a clinician and a medical device engineer and team manager to continuously challenge and complement each other. 

With a mutual understanding that surgical options in glaucoma had not advanced in decades, Malik and Glenn have always had a strong desire to contribute to new innovations which inevitably led both to SpyGlass Pharma™ today.

Read more about founding SpyGlass at The OphthalmologistJoining Forces: Start-up Success. A chance meeting that led to over a decade of collaboration and innovation

spyglass_leadership_team_edited.png

Our Team.

Behind our accomplished scientists and engineers is a seasoned leadership team with deep roots in ophthalmology, IOL development, and commercial success. SpyGlass Pharma™ is led by a proven team with science, R&D, communications, and operations expertise.

malik_kahook_md.jpg

Malik Y. Kahook, MD

Co-founder, President and Executive Chair of the Board

  • LinkedIn

Dr. Kahook is a practicing ophthalmologist and serial entrepreneur with 15 years of startup and academic experience in research and development. Several of his devices are currently commercialized for clinical use. ClarVista Medical, acquired by Alcon in 2017, developed an advanced modular intraocular lens system co-invented by Dr. Kahook. He is the inventor of the Kahook Dual Blade, which is marketed globally by New World Medical. Dr. Kahook also has extensive experience in intraocular lens material innovation and novel ophthalmic drug delivery methods. His inventions have been the focus of over $150 million in venture backed funding and industry led development and commercialization since 2008 and his devices have been used to treat hundreds of thousands of patients globally. 

patrick_mooney.jpg

Patrick Mooney

Chief Executive Officer

  • Grey LinkedIn Icon

Patrick Mooney is a seasoned leader in ophthalmology, having led several launches and commercialization efforts of ophthalmic pharmaceuticals and medical devices. Most recently, he was Vice President and Head of the Ophthalmology Franchise at Novartis where he was responsible for the overall strategy and growth of U.S. Ophthalmic Pharmaceuticals. Prior to Novartis, he led sales for Galderma’s Self Medication business unit and was with Alcon for 16 years, holding leadership positions of increasing responsibility in sales, marketing and operations in the United States and Asia. Patrick’s leadership experience in eye care spans the surgical, vision-care and pharmaceutical spectrum, and includes product launches in Retina, Glaucoma, Dry Eye as well as medical devices. Patrick is highly regarded across the industry for his deep insight in the eye care marketplace, his passion for developing and commercializing new products and therapies that improve the lives of patients, and for his focus on developing people, and creating a strong team culture that yields successful business outcomes.

genn_sussman.jpg

Glenn Sussman

Co-founder and Chief Technology Officer

  • Grey LinkedIn Icon

Glenn Sussman is a serial inventor and entrepreneur with 30+ years of experience in the ophthalmic space. Prior to co-founding SpyGlass, he was responsible for the development of a novel IOL for ClarVista Medical which was acquired by Alcon in 2017. Glenn previously served in an R&D leadership role at Alcon for 18 years. He has supported and led development for several other industry leaders and academic facilities. Glenn has over 60 issued US patents in areas that range from intraocular lenses to surgical devices for ophthalmic surgery.

margot_goodkin_md.jpg

Margot Goodkin, MD PhD

Chief Medical Officer

  • Grey LinkedIn Icon

Dr. Goodkin is a biopharmaceutical industry veteran with experience throughout the ophthalmic development space. She completed her residency training at the University of Pennsylvania’s Scheie Eye Institute, followed by a glaucoma fellowship at the Bascom Palmer Eye Institute. Prior to joining industry, Dr. Goodkin was a Medical Officer in the Division of Ophthalmic, Neurological and ENT Devices at the US FDA Center for Devices and Radiological Health, covering clinical trials of ophthalmic lasers and minimally invasive implants for management of glaucoma (MIGS). Dr. Goodkin joined Allergan (subsequently acquired by AbbVie) in 2010, where she served in leadership roles on several successful clinical programs and a number of corporate initiative teams as an Executive Director of Clinical Development. She was a key member of the team that developed Durysta®, the first intracameral sustained-release therapy approved in the US to lower IOP in patients with glaucoma and ocular hypertension. Dr. Goodkin remains involved academically as an active member of clinical and scientific research societies, and applies her breadth of experience outside of SpyGlass as a member of the Research Committee of the Glaucoma Research Foundation and the Executive Board of the KCNT1 Epilepsy Foundation.

james_dennewill.jpg

James Dennewill

Chief Operating Officer

  • Grey LinkedIn Icon

James Dennewill brings over 20 years of medical device industry experience, specializing in the development of products, people and processes required to bring new technologies to market. Prior to SpyGlass, he spent over six years with Cianna Medical (acquired by Merit Medical), where he held various positions of escalating responsibility including VP of Operations and COO. James also spent over 10 years with Med-Logics, Inc., where he managed the development of ophthalmic products, resulting in a range of U.S. and international patents, and served as Management Representative for all regulatory affairs.

Our Scientific Advisors

Partnering with some of the top names in cataract and glaucoma ophthalmic care, our advisors help ensure SpyGlass Pharma™'s optimal quality, safety, and delivery for ophthalmic patients worldwide.

nathan_radcliffe_md.jpg

Nathan Radcliffe, MD

New York Eye Surgery Center

Nathan M. Radcliffe, MD, is a glaucoma and cataract surgeon who practices in the Bronx and New York City. After graduating Alpha Omega Alpha from Temple University School of Medicine, Dr. Radcliffe completed his Internship at the University of Hawaii before his residency at New York University. His glaucoma fellowship was through the New York Eye and Ear Infirmary. He was the Glaucoma Service Director at Cornell from 2008-2014 and at NYU and Bellevue Hospital from 2014 to 2016. Dr. Radcliffe is currently an Associate Professor of Ophthalmology at Icahn School of Medicine at Mount Sinai. Dr. Radcliffe has published over 70 peer-reviewed publications in glaucoma research and is a principal investigator and medical monitor for many ongoing prospective trials for new glaucoma treatments. He is committed to teaching others, particularly in the area of microincisional glaucoma surgery (MIGS) and drug delivery. Dr. Radcliffe proudly serves on the glaucoma Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS) and is the 2023 ASCRS Glaucoma Subspecialty Day Course Co-Director. He is the Chief Medical Editor of the Glaucoma Physician publication and is a board member of the Outpatient Ophthalmic Surgery Society.

sam_garg_md.jpg

Sam Garg, MD

Gavin Herbert Eye Institute/UC Irvine

Dr. Sumit (Sam) Garg is Vice Chair of Clinical Ophthalmology, Medical Director, and Professor in Cataract, Refractive, External Disease and Corneal Surgery at the Gavin Herbert Eye Institute at the University of California, Irvine. Dr. Garg participates in numerous research projects, many of which he has presented at national and international meetings. He has been invited to lecture at meetings and symposia locally, nationally and internationally. In addition to his research activities, Dr. Garg has authored numerous peer-reviewed papers and book chapters. Dr. Garg served as chair of the ASCRS Young Eye Surgeons clinical committee, is currently on the ASCRS Cornea clinical committee and is Chief Medical Editor for EyeWorld. Additionally, he serves as special advisor to the National Keratoconus Foundation and co-chair of the ophthalmic advisory board for Beyond Blindness (formerly known as the Blind Children’s Learning Center of Orange County). He has been recognized in Best Doctors and Super Doctors "Rising Stars” yearly since 2013 and has received the Orange County Medical Association’s Physician of Excellence award since 2014. Additionally, he was chosen by Ocular Surgery News as a Premier 300 Refractive Cataract Surgeon. Dr. Garg is actively involved in resident and fellow teaching. In 2014, Dr. Garg published a textbook entitled, “Ophthalmic Microsurgery: Principles, Techniques, and Applications,” a manual designed for the education of ophthalmology trainees. Dr. Garg is a highly-skilled clinician, surgeon, and teacher, and has particular expertise in refractive cataract surgery, complication management, ocular surface disease, corneal (PKP, FLEK, DSEK, DMEK, corneal crosslinking), conjunctival, and refractive surgery.

preeya_gupta_md.jpg

Preeya Gupta, MD

Triangle Eye Consultants

Preeya K. Gupta, MD, is the Managing Director of Triangle Eye Consultants in Raleigh, NC and an Adjunct Associate Professor of Ophthalmology at Tulane University School of Medicine. Dr. Gupta previously served on the faculty at Duke University Eye Center as a Tenured Associate Professor of Ophthalmology from 2011-2021. Dr Gupta earned her medical degree at Northwestern University’s Feinberg School of Medicine in Chicago, and graduated with Alpha Omega Alpha honors. She fulfilled her residency in ophthalmology at Duke University Eye Center in Durham, North Carolina, where she earned the K. Alexander Dastgheib Surgical Excellence Award, and then completed a fellowship in Cornea and Refractive Surgery at Minnesota Eye Consultants in Minneapolis. Dr Gupta has authored many articles in the peer-reviewed literature and serves as an invited reviewer to journals such as Ophthalmology, American Journal of Ophthalmology, and Journal of Refractive Surgery. She has also written several book chapters about corneal disease and ophthalmic surgery, as well as served as an editor of the well-known series, Curbside Consultation in Cataract Surgery. She also holds several editorial board positions including the ONE Network of the American Academy of Ophthalmology, International Society of Refractive Surgery Multimedia Board, and BCSC Refractive Surgery Committee Board. Dr. Gupta serves as an elected member of the American Society of Cataract and Refractive Surgery (ASCRS) Cornea clinical committee, and is also the President of the Vanguard Ophthalmology Society. She has given presentations both nationally and internationally, including invited lectures, national meeting presentations and education of residents and fellows. Dr Gupta has been awarded the National Millennial Eye Outstanding Female in Ophthalmology Award and has received the AAO Achievement Award. She is also an elected American Academy of Ophthalmology (AAO) Council member.

robert_cionni_md.jpg

Robert Cionni, MD

The Eye Institute of Utah

Dr Cionni has over 3 decades of surgical ophthalmology experience specializing in cataract surgery, lens implants, and refractive surgeries such as LASIK, PRK, implantation of ICLs and refractive lens exchange. Throughout the span of his practice, he has innovated new techniques and technologies and consulted with numerous well-known and start-up companies to bring new technologies to market. Dr. Cionni served as the 2015-2016 President of the American Society of Cataract and Refractive Surgery. He has also been a member of many professional organizations, including the Utah Ophthalmology Society, the Utah Medical Association, Cincinnati Academy of Medicine, the Ohio State Medical Association, the Cincinnati Society of Ophthalmology, and the International Intraocular Implant Club. Though recently retired from surgical practice, Dr Cionni continues to work with and consult with companies to develop new and innovative technologies.

Cathleen McCabe.jpg

 Cathleen McCabe, MD 

 Eye Health America

Cathleen McCabe, MD serves as Chief Medical Officer at Eye Health America™. She is one of the foremost eye surgeons today, specializing in complex and premium cataract and refractive surgery at The Eye Associates in Sarasota, Florida. She has a keen interest in advancing the field of ophthalmology and has participated in numerous clinical trials, including innovations in intraocular lenses, perioperative medications, medications and devices to treat glaucoma, dry eye treatments and presbyopia correction. Dr. McCabe continues to receive many prestigious and esteemed awards for her work in Ophthalmology, including being named a Castle Connolly Top Doctor – 2015 to 2022 for Ophthalmology. Castle Connolly also selected her for the first-ever Exceptional Women In Medicine Award for 2017 to 2022. In 2023, Newsweek included Dr. McCabe in the list of national top ophthalmologists She was named to the OSN Premier Surgeon 300 List, and the Premier Surgeon 250 List of Leading Innovators in Premium IOL Cataract Surgery. She was also chosen a LASERVISION Top 100 LASIK Surgeon, elected President of CEDARS/ASPEN-2017, has received the American Academy of Ophthalmology Achievement and Secretariat Awards, is the Immediate Past President of the Outpatient Ophthalmic Surgery Society, the chair of the Refractive Surgery Clinical Committee for the American Society of Cataract and Refractive Surgery (ASCRS), serves on the governing board of ASCRS and serves on numerous editorial and subspecialty boards and committees. She has leadership positions in mentoring and international educational organizations, serves as Chief Medical Editor for Ophthalmic ASC Magazine and Cataract Refractive Surgery Today, co-chairs the OR Waste Task Force Committee, is an advisory board member of EyeSustain, and is an advisor to many ophthalmology industry partners. She is passionate about giving back to her local community, her profession and globally and participates in charitable giving and volunteer efforts both at home and abroad. She is a board member of several charitable foundations in ophthalmology, including One World Global Health/Sight for Life, OOSS Gives, and others. Dr. McCabe received her medical degree from the Medical College of Wisconsin and received her residency training at the prestigious Bascom Palmer Eye Institute at the University of Miami’s School of Medicine. She continues to share her expertise by publishing articles and book chapters as well as lecturing at national and international ophthalmological seminars.

tom_frinzi.jpg

Tom Frinzi

Health Care Advisor

Thomas Frinzi has 40 years of med device experience with a keen focus in ophthalmology. He is the former Worldwide President, Surgical, Johnson & Johnson Vision business, which includes a broad ophthalmology portfolio across the areas of cataracts, refractive surgery (LASIK) and dry eye. Tom was appointed to his position in February 2017 at the conclusion of Johnson & Johnson’s acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. Mr. Frinzi joined AMO in January 2016 as Senior Vice President of Abbott Laboratories and President, Abbott Medical Optics. Having retired in December, 2019 Mr. Frinzi is a member of several BOD’s in the eye space including Staar Surgical, a company specializing in lens based refractive Surgery. Prior to joining Abbott, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. Most recently, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Johnson & Johnson. In recognition of his leadership, expertise and vision in the field, Mr. Frinzi has been awarded the following accolades: Awarded the 2015 Ophthalmology Innovation Award by the Ophthalmology Innovation Summit (OIS); Inducted into the International Intra-Ocular Implant Club (IIIC) in 2017; Awarded the ICONS of Industry Award in 2017 by the Intraocular Implant & Refractive Society, India (IIRSI); voted Top 100 Most Influential People in the World of Ophthalmology by The Ophthalmologist publication for 2018 and received the David Dulaney/AECOS Lifetime Achievement award in 2020. He earned a bachelor's degree in political science from the University of Tampa.

Our Financial Backers

Our vision is fully backed by the outstanding trust and financial support of New Enterprise Associates and Vensana Capital

NEA.jpg
vensana.jpg
RACAPITAL.jpg
Samsara.jpg
vertex_ventures.png
texture_bg.jpg

SpyGlass Pharma™ Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform

ALISO VIEJO, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced the appointments of Margot Goodkin, M.D., Ph.D., as Chief Medical Officer and Bilal Khan, MBA, to the SpyGlass Board of Directors. Dr. Goodkin and Mr. Khan each bring a wealth of experience to support the growth and continued development of the SpyGlass intraocular drug delivery platform. (View full press release)

bottom of page